IBRX · Immunitybio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.21M | - | $32.06M | $26.43M | $16.52M | - | $6.11M | $1.05M | $40.0K | - |
| Cost of Revenue | $238.0K | - | $177.0K | $136.0K | $0 | - | $0 | $0 | - | - |
| Gross Profit | $43.97M | - | $31.88M | $26.29M | $16.52M | - | $6.11M | $1.05M | - | - |
| R&D | - | - | - | - | - | - | $50.44M | $51.13M | $53.35M | - |
| SG&A | - | - | - | - | - | - | $35.92M | $49.25M | $41.88M | - |
| Total Operating Expenses | $114.00M | - | $87.69M | $100.38M | $95.24M | - | $86.36M | $100.38M | $95.24M | - |
| D&A | $4.38M | - | $3.40M | $3.40M | $3.83M | - | $3.90M | $3.90M | $4.55M | - |
| Operating Income | ($69.79M) | - | ($55.63M) | ($71.28M) | ($64.43M) | - | ($80.25M) | ($99.33M) | ($95.20M) | - |
| Interest Expense | - | - | $15.26M | $15.47M | $15.31M | - | $29.32M | $29.79M | $29.48M | - |
| Income Tax | $9.0K | - | ($35.0K) | $269.0K | ($234.0K) | - | $0 | $0 | $0 | - |
| Net Income | ($632.78M) | - | ($67.25M) | ($92.56M) | ($129.65M) | - | ($85.73M) | ($134.56M) | ($134.11M) | - |
| EPS - Basic | ($0.62) | - | ($0.07) | ($0.10) | ($0.15) | - | ($0.12) | ($0.20) | ($0.20) | - |
| EPS - Diluted | ($0.62) | - | ($0.07) | ($0.10) | ($0.15) | - | ($0.14) | ($0.20) | ($0.20) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $205.19M | $88.33M | $60.24M | $137.66M | $60.66M | $143.43M | $111.97M | $130.10M | $133.03M | $265.45M |
| Accounts Receivable | $43.27M | $42.57M | $32.02M | $22.13M | $17.03M | $2.36M | $4.17M | $0 | - | - |
| Inventory | $547.0K | $910.0K | $6.70M | $6.64M | $8.44M | $8.27M | $1.96M | $0 | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $452.95M | $314.88M | $329.50M | $208.13M | $109.16M | $184.59M | $163.15M | $242.83M | $195.72M | $294.08M |
| Total Assets | $646.64M | $501.90M | $518.99M | $402.08M | $303.76M | $382.93M | $364.57M | $444.32M | $400.68M | $504.45M |
| Current Liabilities | $67.95M | $61.75M | $57.13M | $50.64M | $49.20M | $54.94M | $60.96M | $62.11M | $53.76M | $58.28M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.52B | $1.00B | $1.04B | $971.89M | $894.24M | $871.06M | $1.11B | $1.14B | $1.09B | $1.09B |
| Stockholders' Equity | ($870.01M) | ($500.47M) | ($524.32M) | ($570.75M) | ($591.43M) | ($489.10M) | ($745.15M) | ($698.39M) | ($692.01M) | ($586.99M) |
| Retained Earnings | ($4.36B) | ($3.73B) | ($3.66B) | ($3.60B) | ($3.50B) | ($3.38B) | ($3.32B) | ($3.23B) | ($3.10B) | ($2.96B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($75.36M) | - | - | - | ($85.91M) | - | - | - | ($106.98M) | - |
| Investing Cash Flow | ($31.65M) | - | - | - | $4.13M | - | - | - | ($35.62M) | - |
| Financing Cash Flow | $223.93M | - | - | - | ($982.0K) | - | - | - | $10.22M | - |
| CapEx | $1.78M | - | - | - | $1.12M | - | - | - | $1.26M | - |
| Free Cash Flow | ($77.14M) | - | - | - | ($87.03M) | - | - | - | ($108.24M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 99.5% | - | 99.4% | 99.5% | 100.0% | - | 100.0% | 100.0% | - | - |
| Operating margin | -157.9% | - | -173.5% | -269.8% | -390.1% | - | -1314.3% | -9487.4% | -237990.0% | - |
| EBITDA margin | -148.0% | - | -162.9% | -256.9% | -366.9% | - | -1250.5% | -9114.9% | -226602.5% | - |
| Net margin | -1431.4% | - | -209.8% | -350.3% | -784.9% | - | -1404.0% | -12852.3% | -335272.5% | - |
| Free cash flow margin | -174.5% | - | - | - | -526.9% | - | - | - | -270607.5% | - |
| FCF / Net income | 0.12 | - | - | - | 0.67 | - | - | - | 0.81 | - |
| R&D / Revenue | - | - | - | - | - | - | 826.1% | 4883.4% | 133377.5% | - |
| SG&A / Revenue | - | - | - | - | - | - | 588.2% | 4704.0% | 104712.5% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -97.9% | - | -13.0% | -23.0% | -42.7% | - | -23.5% | -30.3% | -33.5% | - |
| Return on equity | 72.7% | - | 12.8% | 16.2% | 21.9% | - | 11.5% | 19.3% | 19.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 6.67 | 5.10 | 5.77 | 4.11 | 2.22 | 3.36 | 2.68 | 3.91 | 3.64 | 5.05 |
| Quick ratio | 6.66 | 5.08 | 5.65 | 3.98 | 2.05 | 3.21 | 2.64 | 3.91 | 3.64 | 5.05 |
| Cash ratio | 3.02 | 1.43 | 1.05 | 2.72 | 1.23 | 2.61 | 1.84 | 2.09 | 2.47 | 4.55 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -3.6x | -4.6x | -4.2x | - | -2.7x | -3.3x | -3.2x | - |
| Equity multiplier | -0.74 | -1.00 | -0.99 | -0.70 | -0.51 | -0.78 | -0.49 | -0.64 | -0.58 | -0.86 |
| Liabilities / Assets | 2.34 | 2.00 | 2.01 | 2.42 | 2.94 | 2.27 | 3.04 | 2.57 | 2.72 | 2.16 |
| Efficiency | ||||||||||
| Asset turnover | 0.07 | - | 0.06 | 0.07 | 0.05 | - | 0.02 | 0.00 | 0.00 | - |
| Inventory turnover | 0.44 | - | 0.03 | 0.02 | 0.00 | - | 0.00 | - | - | - |
| Days sales outstanding | 357d | - | 364d | 306d | 376d | - | 250d | 0d | - | - |
| Days inventory outstanding | 839d | - | 13823d | 17821d | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | 178.2x | - | 72.6x | 88.7x | 155.5x | - | 425.2x | 4146.6x | 90327.6x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 167.6% | - | 425.1% | 2423.9% | 41192.5% | - | 7346.3% | 2453.7% | -88.9% | - |
| Revenue CAGR (3y) | 397.0% | - | 547.7% | 810.6% | 956.7% | - | 352.3% | 45.6% | -34.0% | - |
| Revenue CAGR (5y) | 216.6% | - | 242.5% | 666.3% | 279.4% | - | 247.8% | 128.0% | 51.6% | - |
| Gross profit growth (YoY) | 166.2% | - | 422.2% | 2410.9% | - | - | - | - | - | - |
| Operating income growth (YoY) | -8.3% | - | 30.7% | 28.2% | 32.3% | - | -0.1% | -16.7% | 14.7% | - |
| Net income growth (YoY) | -388.1% | - | 21.6% | 31.2% | 3.3% | - | 10.3% | 2.4% | -15.3% | - |
| EPS growth (YoY) | -313.3% | - | 50.0% | 50.0% | 25.0% | - | 26.3% | 37.5% | 25.9% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 11.4% | - | - | - | 19.6% | - | - | - | -16.7% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -47.1% | -2.3% | 29.6% | 18.3% | 14.5% | 16.7% | -81.0% | -8.8% | -30.8% | -31.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$113.29M totalReportable Segment$113.29M · 100.0%
Product / service
$113.29M totalProduct$112.98M · 99.7%
Product And Service Other$306.0K · 0.3%
Geographic
$113.29M totalUS$113.01M · 99.8%
Europe$278.0K · 0.2%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing ImmunityBio against the 5 most active filers in the same SIC group.